EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Joined: Sep 11, 2007 Posts: 488 Location: southern California
Posted: Thu Feb 07, 2008 2:37 pm Post subject: Copaxone cuts risk of developing MS-
-In 481 patients presenting with a first flare and confirming MRI, but no definitive diagnosis.
In the interim analysis, the proportion of patients developing clinically definite multiple sclerosis (re: a second flare) was 43 percent in the placebo group compared with 25 percent in the Copaxone group, Teva said.
For those that received a clinical diagnosis of MS- the second attack was delayed to 722 days, vs. the 2nd attack average of 366 days in the placebo group-
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
